Want to see SRZN full AI Analyst Report?
SRZN Stock Chart & Stats
$31.56
$0.24(1.85%)
At close: 4:00 PM EST
$31.56
$0.24(1.85%)
Day’s Range― - ―
52-Week Range$8.20 - $35.00
Previous CloseN/A
Volume12.23K
Average Volume (3M)25.24K
Market Cap
$254.03M
Enterprise Value$79.63M
Total Cash (Recent Filing)$106.91M
Total Debt (Recent Filing)$6.78M
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Aug 06, 2026EPS Estimate
-1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.33
Shares Outstanding11,610,371
10 Day Avg. Volume29,706
30 Day Avg. Volume25,240
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.90
Price to Sales (P/S)48.61
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue10.63
Enterprise Value/Gross Profit10.72
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$43.33Price Target Upside37.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.98
Revenue Forecast (FY)$6.40M
Bulls Say, Bears Say
Bulls Say
Targeted Wnt Signaling PlatformSurrozen’s focused platform targeting Wnt signaling is a durable competitive asset: modulating a core regenerative pathway can address multiple epithelial-tissue diseases, supporting a multi-product pipeline and partnership opportunities. Platform-driven R&D creates long-term optionality beyond any single asset.
Recent Revenue Rebound & Positive Gross ProfitA TTM revenue rebound and recent positive gross profit indicate early ability to generate collaborator or milestone revenue and to cover direct costs. This structural sign of commercial traction, even if small, improves scalability prospects and reduces sole reliance on financing for incremental program spend.
Low Absolute Debt BurdenModest absolute debt reduces near-term interest and covenant risk and preserves flexibility relative to highly leveraged peers. While equity financing dependence remains, low debt lessens chances of distress from fixed obligations, supporting operational continuity during prolonged development timelines.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flow at ~-$33M TTM is a structural weakness: it necessitates frequent external financing or large partnerships, risks dilution, and can delay or scale back clinical programs if capital markets tighten. Cash burn constrains strategic optionality over the medium term.
Negative Shareholders' EquityNegative shareholders’ equity reflects accumulated losses that have eroded the capital base, reducing financial flexibility. This structural impairment limits borrowing capacity, complicates negotiations with partners or investors, and raises the probability of dilutive financings to sustain operations.
Large Ongoing Operating LossesExtremely negative margins and persistent operating losses show the current cost structure far exceeds revenue capability. Absent a material shift—such as major partnership revenue, product approval, or significant cost restructuring—the company lacks a credible near-term path to breakeven, stressing long-term viability.
Surrozen News
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $8.20 and its highest was $35.00 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $254.03M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is Aug 06, 2026 which is in 21 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on May 06, 2026. The company reported -$11.65 earnings per share for the quarter, missing the consensus estimate of -$1.092 by -$10.558.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -1.29.
How many shares outstanding does Surrozen have?
Surrozen has 11,610,371 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of -$11.65 in its last earnings report, missing expectations of -$1.092. Following the earnings report the stock price went down -9.903%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Surrozen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.33 (37.30% Upside)
$43.33 (37.30% Upside)
Hedge Fund Trend
Increased
By 226.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
309.79%
Trailing 12-Months
Asset Growth
5.12%
Trailing 12-Months
Company Description
Surrozen
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
SRZN Stock 12 Month Forecast
Average Price Target
$43.33
▲(37.30% Upside)
Technical Analysis
Opus Genetics
―
Ovid Therapeutics
―
Shattuck Labs
―
Spruce Biosciences
―
Biomea Fusion
―
Ownership Overview
45.74% Insiders
2.87% Mutual Funds
6.48% Other Institutional Investors
43.41% Public Companies and
Individual Investors